                         SEQUENCE LISTING

<110>  OREGA BIOTECH
       INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
 
<120>  Methods of Treating And/or Preventing Cell Proliferation 
       Disorders with IL-17 Antagonists

<130>  O57-B-33883 PCT

<150>  61/334,979
<151>  2010-05-14

<160>  8     

<170>  PatentIn version 3.5

<210>  1
<211>  155
<212>  PRT
<213>  Homo sapiens

<220>
<223>  HUMAN IL-17 AMINO ACID 

<400>  1

Met Thr Pro Gly Lys Thr Ser Leu Val Ser Leu Leu Leu Leu Leu Ser 
1               5                   10                  15      


Leu Glu Ala Ile Val Lys Ala Gly Ile Thr Ile Pro Arg Asn Pro Gly 
            20                  25                  30          


Cys Pro Asn Ser Glu Asp Lys Asn Phe Pro Arg Thr Val Met Val Asn 
        35                  40                  45              


Leu Asn Ile His Asn Arg Asn Thr Asn Thr Asn Pro Lys Arg Ser Ser 
    50                  55                  60                  


Asp Tyr Tyr Asn Arg Ser Thr Ser Pro Trp Asn Leu His Arg Asn Glu 
65                  70                  75                  80  


Asp Pro Glu Arg Tyr Pro Ser Val Ile Trp Glu Ala Lys Cys Arg His 
                85                  90                  95      


Leu Gly Cys Ile Asn Ala Asp Gly Asn Val Asp Tyr His Met Asn Ser 
            100                 105                 110         


Val Pro Ile Gln Gln Glu Ile Leu Val Leu Arg Arg Glu Pro Pro His 
        115                 120                 125             


Cys Pro Asn Ser Phe Arg Leu Glu Lys Ile Leu Val Ser Val Gly Cys 
    130                 135                 140                 


Thr Cys Val Thr Pro Ile Val His His Val Ala 
145                 150                 155 


<210>  2
<211>  468
<212>  DNA
<213>  Homo sapiens


<220>
<223>  HUMAN IL-17 mRNA 

<400>  2
atgactcctg ggaagacctc attggtgtca ctgctactgc tgctgagcct ggaggccata       60

gtgaaggcag gaatcacaat cccacgaaat ccaggatgcc caaattctga ggacaagaac      120

ttcccccgga ctgtgatggt caacctgaac atccataacc ggaataccaa taccaatccc      180

aaaaggtcct cagattacta caaccgatcc acctcacctt ggaatctcca ccgcaatgag      240

gaccctgaga gatatccctc tgtgatctgg gaggcaaagt gccgccactt gggctgcatc      300

aacgctgatg ggaacgtgga ctaccacatg aactctgtcc ccatccagca agagatcctg      360

gtcctgcgca gggagcctcc acactgcccc aactccttcc ggctggagaa gatactggtg      420

tccgtgggct gcacctgtgt caccccgatt gtccaccatg tggcctaa                   468


<210>  3
<211>  137
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Recombinant human IL-17  

<400>  3

Met Ile Val Lys Ala Gly Ile Thr Ile Pro Arg Asn Pro Gly Cys Pro 
1               5                   10                  15      


Asn Ser Glu Asp Lys Asn Phe Pro Arg Thr Val Met Val Asn Leu Asn 
            20                  25                  30          


Ile His Asn Arg Asn Thr Asn Thr Asn Pro Lys Arg Ser Ser Asp Tyr 
        35                  40                  45              


Tyr Asn Arg Ser Thr Ser Pro Trp Asn Leu His Arg Asn Glu Asp Pro 
    50                  55                  60                  


Glu Arg Tyr Pro Ser Val Ile Trp Glu Ala Lys Cys Arg His Leu Gly 
65                  70                  75                  80  


Cys Ile Asn Ala Asp Gly Asn Val Asp Tyr His Met Asn Ser Val Pro 
                85                  90                  95      


Ile Gln Gln Glu Ile Leu Val Leu Arg Arg Glu Pro Pro His Cys Pro 
            100                 105                 110         


Asn Ser Phe Arg Leu Glu Lys Ile Leu Val Ser Val Gly Cys Thr Cys 
        115                 120                 125             


Val Thr Pro Ile Val His His Val Ala 
    130                 135         


<210>  4
<211>  285
<212>  PRT
<213>  Homo sapiens

<220>
<223>  Human BAFF Isoform 1 

<400>  4

Met Asp Asp Ser Thr Glu Arg Glu Gln Ser Arg Leu Thr Ser Cys Leu 
1               5                   10                  15      


Lys Lys Arg Glu Glu Met Lys Leu Lys Glu Cys Val Ser Ile Leu Pro 
            20                  25                  30          


Arg Lys Glu Ser Pro Ser Val Arg Ser Ser Lys Asp Gly Lys Leu Leu 
        35                  40                  45              


Ala Ala Thr Leu Leu Leu Ala Leu Leu Ser Cys Cys Leu Thr Val Val 
    50                  55                  60                  


Ser Phe Tyr Gln Val Ala Ala Leu Gln Gly Asp Leu Ala Ser Leu Arg 
65                  70                  75                  80  


Ala Glu Leu Gln Gly His His Ala Glu Lys Leu Pro Ala Gly Ala Gly 
                85                  90                  95      


Ala Pro Lys Ala Gly Leu Glu Glu Ala Pro Ala Val Thr Ala Gly Leu 
            100                 105                 110         


Lys Ile Phe Glu Pro Pro Ala Pro Gly Glu Gly Asn Ser Ser Gln Asn 
        115                 120                 125             


Ser Arg Asn Lys Arg Ala Val Gln Gly Pro Glu Glu Thr Val Thr Gln 
    130                 135                 140                 


Asp Cys Leu Gln Leu Ile Ala Asp Ser Glu Thr Pro Thr Ile Gln Lys 
145                 150                 155                 160 


Gly Ser Tyr Thr Phe Val Pro Trp Leu Leu Ser Phe Lys Arg Gly Ser 
                165                 170                 175     


Ala Leu Glu Glu Lys Glu Asn Lys Ile Leu Val Lys Glu Thr Gly Tyr 
            180                 185                 190         


Phe Phe Ile Tyr Gly Gln Val Leu Tyr Thr Asp Lys Thr Tyr Ala Met 
        195                 200                 205             


Gly His Leu Ile Gln Arg Lys Lys Val His Val Phe Gly Asp Glu Leu 
    210                 215                 220                 


Ser Leu Val Thr Leu Phe Arg Cys Ile Gln Asn Met Pro Glu Thr Leu 
225                 230                 235                 240 


Pro Asn Asn Ser Cys Tyr Ser Ala Gly Ile Ala Lys Leu Glu Glu Gly 
                245                 250                 255     


Asp Glu Leu Gln Leu Ala Ile Pro Arg Glu Asn Ala Gln Ile Ser Leu 
            260                 265                 270         


Asp Gly Asp Val Thr Phe Phe Gly Ala Leu Lys Leu Leu 
        275                 280                 285 


<210>  5
<211>  858
<212>  DNA
<213>  Homo sapiens

<220>
<223>  Human BAFF Isoform 1 mRNA

<400>  5
atggatgact ccacagaaag ggagcagtca cgccttactt cttgccttaa gaaaagagaa       60

gaaatgaaac tgaaggagtg tgtttccatc ctcccacgga aggaaagccc ctctgtccga      120

tcctccaaag acggaaagct gctggctgca accttgctgc tggcactgct gtcttgctgc      180

ctcacggtgg tgtctttcta ccaggtggcc gccctgcaag gggacctggc cagcctccgg      240

gcagagctgc agggccacca cgcggagaag ctgccagcag gagcaggagc ccccaaggcc      300

ggcctggagg aagctccagc tgtcaccgcg ggactgaaaa tctttgaacc accagctcca      360

ggagaaggca actccagtca gaacagcaga aataagcgtg ccgttcaggg tccagaagaa      420

acagtcactc aagactgctt gcaactgatt gcagacagtg aaacaccaac tatacaaaaa      480

ggatcttaca catttgttcc atggcttctc agctttaaaa ggggaagtgc cctagaagaa      540

aaagagaata aaatattggt caaagaaact ggttactttt ttatatatgg tcaggtttta      600

tatactgata agacctacgc catgggacat ctaattcaga ggaagaaggt ccatgtcttt      660

ggggatgaat tgagtctggt gactttgttt cgatgtattc aaaatatgcc tgaaacacta      720

cccaataatt cctgctattc agctggcatt gcaaaactgg aagaaggaga tgaactccaa      780

cttgcaatac caagagaaaa tgcacaaata tcactggatg gagatgtcac attttttggt      840

gcattgaaac tgctgtga                                                    858


<210>  6
<211>  266
<212>  PRT
<213>  Homo sapiens

<220>
<223>  Human BAFF Isoform 2 

<400>  6

Met Asp Asp Ser Thr Glu Arg Glu Gln Ser Arg Leu Thr Ser Cys Leu 
1               5                   10                  15      


Lys Lys Arg Glu Glu Met Lys Leu Lys Glu Cys Val Ser Ile Leu Pro 
            20                  25                  30          


Arg Lys Glu Ser Pro Ser Val Arg Ser Ser Lys Asp Gly Lys Leu Leu 
        35                  40                  45              


Ala Ala Thr Leu Leu Leu Ala Leu Leu Ser Cys Cys Leu Thr Val Val 
    50                  55                  60                  


Ser Phe Tyr Gln Val Ala Ala Leu Gln Gly Asp Leu Ala Ser Leu Arg 
65                  70                  75                  80  


Ala Glu Leu Gln Gly His His Ala Glu Lys Leu Pro Ala Gly Ala Gly 
                85                  90                  95      


Ala Pro Lys Ala Gly Leu Glu Glu Ala Pro Ala Val Thr Ala Gly Leu 
            100                 105                 110         


Lys Ile Phe Glu Pro Pro Ala Pro Gly Glu Gly Asn Ser Ser Gln Asn 
        115                 120                 125             


Ser Arg Asn Lys Arg Ala Val Gln Gly Pro Glu Glu Thr Gly Ser Tyr 
    130                 135                 140                 


Thr Phe Val Pro Trp Leu Leu Ser Phe Lys Arg Gly Ser Ala Leu Glu 
145                 150                 155                 160 


Glu Lys Glu Asn Lys Ile Leu Val Lys Glu Thr Gly Tyr Phe Phe Ile 
                165                 170                 175     


Tyr Gly Gln Val Leu Tyr Thr Asp Lys Thr Tyr Ala Met Gly His Leu 
            180                 185                 190         


Ile Gln Arg Lys Lys Val His Val Phe Gly Asp Glu Leu Ser Leu Val 
        195                 200                 205             


Thr Leu Phe Arg Cys Ile Gln Asn Met Pro Glu Thr Leu Pro Asn Asn 
    210                 215                 220                 


Ser Cys Tyr Ser Ala Gly Ile Ala Lys Leu Glu Glu Gly Asp Glu Leu 
225                 230                 235                 240 


Gln Leu Ala Ile Pro Arg Glu Asn Ala Gln Ile Ser Leu Asp Gly Asp 
                245                 250                 255     


Val Thr Phe Phe Gly Ala Leu Lys Leu Leu 
            260                 265     


<210>  7
<211>  801
<212>  DNA
<213>  Homo sapiens

<220>
<223>  Human BAFF Isoform 2 mRNA

<400>  7
atggatgact ccacagaaag ggagcagtca cgccttactt cttgccttaa gaaaagagaa       60

gaaatgaaac tgaaggagtg tgtttccatc ctcccacgga aggaaagccc ctctgtccga      120

tcctccaaag acggaaagct gctggctgca accttgctgc tggcactgct gtcttgctgc      180

ctcacggtgg tgtctttcta ccaggtggcc gccctgcaag gggacctggc cagcctccgg      240

gcagagctgc agggccacca cgcggagaag ctgccagcag gagcaggagc ccccaaggcc      300

ggcctggagg aagctccagc tgtcaccgcg ggactgaaaa tctttgaacc accagctcca      360

ggagaaggca actccagtca gaacagcaga aataagcgtg ccgttcaggg tccagaagaa      420

acaggatctt acacatttgt tccatggctt ctcagcttta aaaggggaag tgccctagaa      480

gaaaaagaga ataaaatatt ggtcaaagaa actggttact tttttatata tggtcaggtt      540

ttatatactg ataagaccta cgccatggga catctaattc agaggaagaa ggtccatgtc      600

tttggggatg aattgagtct ggtgactttg tttcgatgta ttcaaaatat gcctgaaaca      660

ctacccaata attcctgcta ttcagctggc attgcaaaac tggaagaagg agatgaactc      720

caacttgcaa taccaagaga aaatgcacaa atatcactgg atggagatgt cacatttttt      780

ggtgcattga aactgctgtg a                                                801


<210>  8
<211>  153
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Recombinant human soluble BAFF

<400>  8

Met Ala Val Gln Gly Pro Glu Glu Thr Val Thr Gln Asp Cys Leu Gln 
1               5                   10                  15      


Leu Ile Ala Asp Ser Glu Thr Pro Thr Ile Gln Lys Gly Ser Tyr Thr 
            20                  25                  30          


Phe Val Pro Trp Leu Leu Ser Phe Lys Arg Gly Ser Ala Leu Glu Glu 
        35                  40                  45              


Lys Glu Asn Lys Ile Leu Val Lys Glu Thr Gly Tyr Phe Phe Ile Tyr 
    50                  55                  60                  


Gly Gln Val Leu Tyr Thr Asp Lys Thr Tyr Ala Met Gly His Leu Ile 
65                  70                  75                  80  


Gln Arg Lys Lys Val His Val Phe Gly Asp Glu Leu Ser Leu Val Thr 
                85                  90                  95      


Leu Phe Arg Cys Ile Gln Asn Met Pro Glu Thr Leu Pro Asn Asn Ser 
            100                 105                 110         


Cys Tyr Ser Ala Gly Ile Ala Lys Leu Glu Glu Gly Asp Glu Leu Gln 
        115                 120                 125             


Leu Ala Ile Pro Arg Glu Asn Ala Gln Ile Ser Leu Asp Gly Asp Val 
    130                 135                 140                 


Thr Phe Phe Gly Ala Leu Lys Leu Leu 
145                 150             


